Sotrovimab, the anti-viral medicine for COVID-19, is 100 per cent effective in preventing death, according to the latest study results released by MoHAP.
It showed that 97 per cent of the recipients recovered within 14 days and prevented ICU admission in 99 per cent of the cases.
The study was carried out between June 30 and July 13 in collaboration with the Abu Dhabi Department of Health and Dubai Health Authority (DHA).
Over 6,100 patients were given the anti-viral medicine, of which 52 per cent were aged 50 or above and had multiple pre-existing medical conditions.
The UAE was one of the first countries to receive the shipment of the medicine and had approved its use in June.


UAE sends humanitarian aid to earthquake-hit Colombia
UAE calls for global action to combat extremism and hate speech
Four UAE aid convoys deliver 781 tonnes of supplies to Gaza
Etihad Rail launches cargo service from Fujairah to Industrial City of Abu Dhabi
H.H. Sheikh Hamdan announces new Acting Director General of Dubai Ruler's Court
RTA completes works on Oud Metha, Al Asayel Streets development project
UAE President, Indian PM discuss stronger bilateral ties
Dubai Police warns of fake online adverts selling Global Village tickets
UAE honours mothers of fallen heroes
Dubai strengthens living standards in workers’ communities
H.H. Sheikh Mohammed explores project documenting history of 'Al Khuzam'
H.H. Sheikh Hamdan stresses need for more specialised jobs for Emiratis
Dubai Police arrests 3, recovers AED 190,000 within minutes of theft
Abu Dhabi expands AI literacy programme across 170+ private schools
UAE President congratulates Ethara team for 'F1 Promoter of the Year' win
UAE-Sweden joint operation targets organised crime network
UAE expands support for Nepal with sixth aid plane
H.H. Sheikh Hamad: 52 years of progress and achievement
RTA and Dubai Airports advance plans for seamless airport connectivity
